Format

Send to

Choose Destination
See comment in PubMed Commons below
Biochimie. 2008 Jan;90(1):173-80. Epub 2007 Jul 17.

Prospects and challenges of building a cancer vaccine targeting telomerase.

Author information

1
Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, 551 BRBII/III, 421 Curie Blvd., Philadelphia, PA 19104, USA. rhv@mail.med.upenn.edu <rhv@mail.med.upenn.edu>

Abstract

Despite their origin from self-tissue, tumor cells can be immunogenic and trigger immune responses that can profoundly influence tumor growth and development. Clinically, it may be possible to amplify or induce anti-tumor immune responses to achieve tumor rejection in patients. Increasing data over the last 8 years suggest that the human telomerase reverse transcriptase hTERT is immunogenic both in vitro and in vivo and may be a suitable target for novel cancer immunotherapy. Peptides derived from hTERT are naturally processed by tumors and presented on MHC molecules and trigger effector functions of specific T lymphocytes. Vaccination of cancer patients against hTERT epitopes induces anti-tumor T cells without clinical toxicity. If second-generation vaccines and other strategies are able to generate optimal cellular immunity against hTERT without toxicity in humans, the possibility of broad-spectrum immunotherapy or even immunoprevention therapy of cancer may be possible.

PMID:
17716803
PMCID:
PMC2745192
DOI:
10.1016/j.biochi.2007.07.005
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center